Navigation Links
Artielle ImmunoTherapeutics Announces Positive Results of Phase 1 Multiple Sclerosis Trial
Date:9/14/2009

>Worldwide, multiple sclerosis (MS) is thought to affect more than 2.5 million people. MS is a chronic autoimmune disease caused when T cells, part of the body's immune system, attack the central nervous system (CNS), which is made up of the brain, spinal cord and optic nerves. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. In MS, activation of these T cells triggers the release of inflammatory cytokines that lead to the destruction of the myelin, the fatty substance that surrounds and protects the nerve fibers in the central nervous system. When any part of the myelin sheath or nerve fiber is damaged or destroyed, nerve impulses traveling to and from the brain and spinal cord are distorted or interrupted, producing the variety of symptoms that can occur. As demonstrated in animal studies, RTL1000 inhibits the activation of myelin-reactive T cells, preventing the release of inflammatory cytokines and causing the release of anti-inflammatory cytokines. Artielle has also shown in models of MS that animals treated with RTL1000 demonstrate repair of the myelin sheath.

About Artielle ImmunoTherapeutics, Inc.

Artielle ImmunoTherapeutics, Inc., headquartered in Portland, Oregon, is a clinical stage biopharmaceutical company with a platform technology for inflammatory diseases. Artielle's core technology has generated a new proprietary class of molecules known as Recombinant T cell receptor Ligands (RTLs) that can be tailored to treat a wide range of autoimmune diseases. The company has recently completed Phase 1 clinical safety trial for lead drug candidate, RTL1000, for multiple sclerosis. In addition to multiple sclerosis, Artielle is also conducting research in various pre-clinical phases on other autoimmune disease to which its platform technology is applicable such as celiac disease, uveitis, rheumatoid arthritis, type 1 diabetes and other diseases. The company's technology
'/>"/>

SOURCE Artielle ImmunoTherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... N.C. , July 2, 2015 ... assets related to the ion channel biology platform from ... been obtained as part of Pfizer,s 2011 acquisition of ... rights to the "Icagen" name and trademark.  XRPro Sciences ... services for ion channel and transporter drug discovery, combining ...
(Date:7/2/2015)... 2015 Research ... addition of the "2015 New Frontiers ... Emerging Technologies, Competitive Landscape" report to ... in Clinical Chemistry and Immunodiagnostics: Global Challenges, ... seven-country strategic analysis of major business opportunities ...
(Date:7/2/2015)... BGI gab heute bekannt, dass ... American College of Pathologists (CAP) akkreditiert wurde. ... klinische Next-Generation-Sequencing Labor, das in ... somit die höchsten Standards an klinischer Laborpraxis ... - 21 CFR Part 11 konformen Laborverfahren ...
Breaking Medicine Technology:Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
(Date:7/3/2015)... ... July 03, 2015 , ... B. ... has been retained to lead a national president recruitment for Regional ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/3/2015)... ... 2015 , ... The Erie County Bar Association Institute of ... Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law Offices. ... these types of cases. , Each year, New York State residents are hospitalized ...
(Date:7/3/2015)... ... , ... Talcum powder attorneys representing clients in national lawsuits announce the launch ... website. Just as the previous version did, the new website will serve as a ... ovarian cancer warning information. The site is routinely updated with news articles on talcum ...
(Date:7/3/2015)... TX (PRWEB) , ... July 03, 2015 , ... ... the United States, named Mariah N. Manzanares, MD as the new Medical Director of ... new facility medical director of our Frisco facility,” said Dr. James M. Muzzarelli, Executive ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at ... that he says will reveal biblical truth and expose popular lies regarding proper relationships ... Say Don’t Have Sex”, immediately goes into the core of the subject by explaining ...
Breaking Medicine News(10 mins):Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... , FRIDAY, Jan. 6 (HealthDay News) -- ... receive recommended care, a new study concludes. For ... diabetes patients who received medical care between 2005 and ... At these centers, free or reduced-cost care is provided ...
... (trade name: Zytiga) has been approved since September 2011 ... longer responsive to hormone therapy and progresses further during ... an early benefit assessment pursuant to the "Act on ... the German Institute for Quality and Efficiency in Health ...
... the progression of interstitial lung disease (ILD) in smokers, ... studies have suggested that statins might be beneficial in ... that they may contribute to the progression of pulmonary ... case reports have suggested that statins may contribute to ...
... , THURSDAY, Jan. 5 (HealthDay News) -- New research suggests ... expectant mothers the gender of their baby as early as the ... its kind, according to the South Korean researchers. They collected ... of pregnancy and concluded that various ratios of two enzymes called ...
... The new edition of America Speaks, a compilation of ... support for research and innovation to improve health, create ... Americans don,t believe we are making enough progress in ... the best health care system in the world. ...
... HealthDay Reporter , THURSDAY, Jan. 5 (HealthDay News) -- Man,s beloved ... humans, dogs can understand and anticipate the intentions of their ... were spoken to or who had direct eye contact with a ... moved across the room than if the person didn,t make direct ...
Cached Medicine News:Health News:Diabetes Care Thwarted by Unstable Health Insurance: Study 2Health News:Abiraterone: Indication of considerable added benefit in certain patients 2Health News:Statins may increase risk of interstitial lung abnormalities in smokers 2Health News:Blood Test May Reveal Child's Sex Soon After Conception 2Health News:Majority of Americans say research and development are key to building US economy 2Health News:Like Babies, Dogs Pick Up on People's Intent 2Health News:Like Babies, Dogs Pick Up on People's Intent 3
Used after ablation to wash away particulate from anterior & posterior sides of flap & stromal bed. Conforms to the corneal flap. .0mm extension with a 11.0mm radius, Angled tip....
Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
...
...
Medicine Products: